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A young researcher’s guide to NME/Nm23/NDP Kinase 
Abstract
Nucleoside diphosphate kinases (NDPKs) catalyze the exchange of the 
terminal phosphate from trinucleotides to dinucleotides through a high-
energy phosphohistidine intermedier. They are encoded by NME genes and 
have been found, with a few exceptions, in all living beings. Besides their 
well-known function as key regulators of the cellular nucleotide homeostasis, 
they have been appointed numerous additional biochemical and biological 
functions. The discovery of NME1/NDPK A as the first metastasis suppres-
sor opened new avenues in cancer research. Although the precise role of NME 
genes/proteins in cancer dissemination is not yet revealed, it seems that fur-
ther intensive research in this field may lead to new advances in cancer di-
agnosis and prognosis, as well as encourage new therapeutic strategies.
INTRODUCTION
Nucleoside-diphosphate kinases (NME/Nm23/NDPK) constitute a family of evolutionary conserved enzymes present in all three 
domains of life (1). The NDPK was discovered in the mid-20th century 
by its biochemical activity consisting of the removal of the terminal 
phosphate from a nucleoside triphosphate (mainly ATP) and its addition 
to all other (d)NDPs. It is generally considered to be a housekeeping 
enzyme since it is in charge of the maintenance of the cellular NTP pool 
(2). A huge interest for this enzyme started in early nineties when it was 
discovered that a gene named nm23 (non-metastatic clone 23, also 
known as NME), responsible for metastasis suppression in the murine 
melanoma model system (3) is actually encoding one of the subunits of 
NDPK, NDPK A. The NME/Nm23/NDPK family members have been 
assigned a vast range of biological functions spanning from metastasis 
suppression, proliferation and development to ciliary functions and ve-
sicular transport (4). Despite comprehensive studies done so far in this 
field, there are still essential questions that have not been answered. The 
exact mechanism by which the members of the NME/Nm23/NDPK 
family execute their biological functions still remains to be unraveled.
Structure, function and intracellular  
localization of NME/NDPK members
Nucleoside diphosphate kinases (NDPKs) catalyze the exchange of 
g-phosphate between triphosphates and diphosphates through a high-
energy phosphohistidine intermedier (5). They are encoded by the NME 
genes. Ten such genes have been found in humans (4). On the basis of 
phylogenetic studies, the exon-intron structure and the presence/absence 
of specific protein domains, the vertebrate NME proteins have been 
separated into two groups (Figure 1) (6).
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NDPK  – nucleoside diphosphate kinase 
MIF  – macrophage migration inhibitory factor 
MDM2  – mouse double minute 2 homolog 
EBNA 1 – 3C – Epstein-Barr nuclear antigen 1–3C 
TGF-b – transforming growth factor b 
LPA1  – lysophosphatidic acid receptor 1 
MPA  – medroxyprogesterone acetate 
STRAP – Serine/Threonine Kinase Receptor  
    Associated Protein 
MLS  – mitochondrial localization signal domain 
TRF1  – Telomeric Repeat Binding Factor 1 
ICAP1a – integrin cytoplasmic domain-associated 
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Group I protein members (NME1-4) are generally 
highly homologous among themselves and compared to 
their orthologs in different species (58-88% amino acid 
homology). Their corresponding genes have a similar ex-
on-intron structure, as well (7). The NME1/NDPK A and 
NME2/NDPK B subunits form the main cellular nucle-
oside diphosphate kinase which executes at least 80% of 
the cellular NDPK function. The identically folded subu-
nits can assemble into enzymatically active hexamers in 
all possible combinations (A6, A5B1,....B6) (2). The 17 
kDa subunits A and B are 88% identical in their amino 
acid sequence.  Both proteins are ubiquitously expressed 
and display mainly cytoplasmic localization but can also 
be found elsewhere in the cell (Figure 2) (8). A transcript 
encoding a longer form of NDPK A (9), as well as a re-
adthrough transcript encoding a part of the NDPK A and 
the complete NDPK B have been reported (10). The third 
gene/protein in the Group I named DR-Nm23 (NME3 
or NDPK C) has also been reported and seems to be at 
least partially localized in the mitochondria. NME3 po-
ssesses a 17 amino acid N-terminal hydrophobic sequen-
ce which could anchor the protein in the membrane but 
it is not considered to be a regular mitochondrial signaling 
sequence (11). The NDPK D (NME4/Nm23-H4) is, 
however, a true mitochondrial NDPK with a canonical 
sequence which targets the protein to mitochondria (12). 
All Group I members exhibit the NDPK activity in their 
hexameric form with similar kinetic parameters. They 
possess nine specific residues that have been essential for 
the stability of the NDP kinase and its activity (13).  Be-
sides this housekeeping role in the synthesis of nucleoside 
triphosphates, the NME/NDPK proteins have been assi-
gned several additional biochemical functions. One of 
them is the His-protein kinase which includes the transfer 
of a high-energy phosphate from the phosphorylated in-
termediate to another protein (14, 15). There has also been 
evidence that the NME proteins may function as trans-
criptional modulators (16), exonucleases (17) and have a 
scaffold function (18). 
NME Group II encompasses NME5-9 and, in con-
trast to the Group I members, they are more divergent 
among themselves (28-45% amino acid identity) and dis-
similar to Group I proteins (25-34% amino acid identity). 
They possess either a single or several NDK domains. 
Their tentative multimeric forms have not yet been eluci-
dated. So far, the enzymatic activity was reported only for 
the NME6 (19), although the evidence for its NDPK ac-
tivity is questionable. Compared to the human NME1 
and NME2, the NME6 protein has seven additional 
Figure 1. Schematic representation of NME proteins domains in 
human and sponge. Proteins are represented on a scale 1:10 (1mm 
= 10 amino acids). The number of amino acids is displayed on the 
right side of the schematic representation of the gene. Protein do-
mains have been indicated with boxes, and each protein has been 
searched against SMART/Pfam databases. Abbreviations of do-
main names are retrieved from SMART/Pfam databases and in-
dicated in the figure. Shortened name MLS stands for mitochon-
drial localization signal domain. 
Figure 2. Subcellular localization of GFP-Nm23-H2. Human melanoma cell line WM793B transfected with pEGFPC1-nm23-H2. Fluorescent 
staining is visible in the cytosol and the nuclei with greater incidence in the cytoplasmic region. Scale bar represents 10 µm.
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residues at the N-terminus and 23 additional residues at 
the C-terminus. It has one extra amino acid at the posi-
tion Leu-30 and three additional residues in the Kpn-loop 
which lies in the catalytic site and is essential for the main-
tenance of the hexameric structure, a prerequisite for the 
NDPK activity. It is also possible that the elongated C-
terminus in NME6 (and NME5 as well) disrupts the 
hexameric form (20). Human NME6 does not possess the 
canonical mitochondrial signaling sequence but potential 
mitochondrial targeting sequences have been observed in 
homologs of NME6 in non-bilaterian metazoans (21). 
The Group II members usually do not possess all nine 
residues considered to be crucial for the NDPK activity. 
They differ considerably from the Group I by having ei-
ther one or several NDK domains (NME7 and NME8 
have two and three NDK domains, respectively), while 
some of the NME representatives have additional do-
mains. Almost all metazoan NME5 proteins possess a 
C-terminal DPY-30 domain, NME7 has a DM10 domain 
while NME8 and NME9 have thioredoxin domains (7). 
The Group II members differ from the Group I members 
especially in the length of their N and C termini (Figure 
1). As mentioned earlier, the NME6 was reported to be 
located in the mitochondria. Interestingly, all members 
of the Group II, except NME6, encode proteins mainly 
located in cilia or flagella of spermatids or spermatozoa 
(22). Their role in these cellular structures remains to be 
elucidated.
Evolutionary history of NME genes/
proteins
It has been suggested that the Group I NME1/2 and 
NME3/4 genes arose from a single ancestor gene common 
to all chordates by the first round of whole genome dupli-
cation (1R) which occurred early in the vertebrate lineage 
(23). NME3 and NME4 arose from a cis-duplication of 
NME3/4 gene that occurred probably before or around 
teleost radiation, while NME1 and NME2 separated 
through cis-duplication after the emergence of amphibi-
ans. Our work (24) suggests that the sponge Group I 
NME gene/protein of the last common ancestor of all 
Metazoans was structurally and functionally similar to 
the multifunctional enzyme it is today. The analysis of the 
sponge NMEGpISd (NME homolog from the marine 
sponge Suberites domuncula) promoter revealed that some 
of the motifs crucial for human promoter activity are also 
present in sponges. Further, the sponge protein has a 
hexameric structure and a NDPK activity similar to the 
human homolog NME1. NMEGpISd shows DNA bind-
ing properties of NME1 and/or NME2 and interacts with 
the human NME1 ortholog/homolog in human cultured 
cells. Moreover, it shows the same subcellular localization 
as the human NME1 and significantly diminishes migra-
tion potential of human cells, which leads to the conclu-
sion that the sponge NME protein can replace the human 
partner in, at least, some biological functions which are 
usually associated with “higher” metazoans. The possible 
function of the NMEGpI (ancestral type protein, the pre-
cursor of Group I proteins) is not yet established in simple 
metazoans but it is possible that it participates in ancient 
precursor processes, which can be viewed as a foundation 
for the complex signaling networks in higher animals. 
Our recent work on the NME homolog from filasterean 
Capsospora owcarzaky, a close unicellular relative of ani-
mals (25) reveals similar features which indicate that the 
NME protein did not change significantly in the transi-
tion to multicellularity.
It has been shown that NME5-8 have already been 
present in the common ancestor of choanoflagellates and 
metazoans and emerged at the time of eukaryote radiation 
(23). Most Group II members are present in early-branch-
ing eukaryote lineages. Two exceptions are NME8, which 
is probably a choanoflagellate/metazoan innovation, and 
NME9, which originated from an incompletely translo-
cated duplication of NME8 after separation of eutherians 
and metatherians. The NME10 displays a separate evolu-
tionary history since it seems that its NDK domain was 
inserted relatively recently (7). The evolutionary studies 
of the Group II genes/proteins underscore their necessity 
in the physiology of every living cell although there has 
been no systematic research to reveal their function.
NME1 – a pioneer in metastasis 
suppression
Since its discovery as the first metastasis suppressor 
gene (3), NME1 has been in focus of scientific research 
(26). In order to inhabit new locations, metastatic cells 
must detach from the original tissue, break through the 
basal lamina and invade the surrounding tissue, enter the 
nearby blood or lymphatic vessels, survive the transit 
through the lymphatic or blood system, extravasate from 
blood/lymphatic vessels into distant tissue and form a 
colony of cells (micrometastasis). Metastasis suppressors 
are specifically involved in regulation of one or several 
steps of this metastatic cascade. The key feature of a me-
tastasis suppressor gene is that its expression inhibits me-
tastasis but it does not influence primary tumor growth. 
Upon restoration of its function, the cell is no longer 
metastatic although it remains tumorigenic (27). In the 
recent years, numerous studies have shown that down-
regulation or even loss of expression of NME1 correlates 
with metastasis formation and poor clinical outcome in 
many tumor types such as breast cancer, melanoma, ovar-
ian carcinoma, hepatocellular and laryngeal carcinoma as 
well as several others (28, 29). The exception to the rule 
is childhood neuroblastoma where overexpression and 
mutation of NME1 (and NME2) were detected and 
linked to poor patient prognosis and unfavorable clinical 
outcome (30, 31). Additionally, hematological malignan-
cies also exhibit similar features: overexpression of NME1 
correlates with disease progression and unfavorable prog-
nosis (32). From these data it is obvious that NME1 plays 
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a tissue-specific role, and, therefore, different regulatory 
mechanisms act in different tumors. It has been reported 
that NME1 is implicated in invasion and colonization 
(33).
Although NME2 was not studied so much in this con-
text, it does exhibit metastasis suppressor activity. It has 
been reported that NME2 has been involved in several 
human cancers including hepatocarcinoma, endometrial 
and cervical carcinoma, leukemia, breast and gastric car-
cinoma, pleural mesothelioma, colorectal, lung, sarcoma, 
and giant cell tumors (34). Similar to NME1, NME2 is 
not only a metastasis suppressor but also may be capable 
of promoting and modulating tumorigenesis in different 
cellular environments. The mechanisms by which either 
of these proteins execute their functions in tumorigenesis 
and metastasis development remain to be elucidated by 
future studies.
NME protein partners
Although being proposed a plethora of biochemical 
functions, the NDPK activity is the only biochemical 
function of the NME proteins that has been thoroughly 
investigated (2). These findings are critically evaluated by 
a part of the scientific community which considers the 
evidence, concerning the relatively vast variety of bio-
chemical functions, to be partial and potentially inade-
quate (35). It is, however, obvious that the vast variety of 
cellular functions in which NME proteins are involved, 
can hardly be explained solely by its enzymatic activity. It 
is more likely that they are a consequence of protein-
protein interactions, or a combination of the two which 
could support the hypothesis that NME proteins may 
suppress tumor metastasis by binding and inactivating 
signaling pathways promoting aggressiveness (35).The 
interacting partners of NME family members include a 
number of oncogenic, viral and cytoskeletal proteins 
which are, considering the diverse NME subcellular lo-
calization, spatially defined (36). In the recent years, the 
most thoroughly investigated members of the NME fam-
ily, NME1 and NME2 have both been reported to inter-
act with dynamin (37). Additionally, NME1 seems to 
interact with prune (38), MIF (39), p53/STRAP (40), 
WHL (41, 42) and a number of small GTPase interacting 
proteins (43). NME2 has been reported to interact with 
TRF1 (44), MDM2 (45),  ICAP1a (46) and several oth-
ers. An excellent review on potential NME partners and 
possible confusion in the interpretation of their interac-
tions has been published by Vlatković et al (36). Although 
having 88% amino acid homology and identical 3D 
structures the two proteins seem to be quite selective in 
choosing their interacting partners which clearly confirms 
that, although forming a functional NDP kinase togeth-
er, each of them participate in distinct signaling pathways 
and execute additional, dissimilar functions in the cell. 
The number of interactions involving NME proteins in 
processes contributing to carcinogenesis is considerable 
and represents a potential pool of biomarkers or therapeu-
tic targets for disease monitoring and treatment. 
Potential translational approaches
Treatment of metastatic cancers is one of the major 
challenges in therapy of malignant diseases. Metastases 
are often inoperable so the choice of treatment relies on 
chemotherapy or radiotherapy with usually very modest 
results and fatal outcome. Therefore, the development of 
new therapeutic strategies for the metastatic disease is of 
utmost importance.
One of the crucial elements of metastasis formation is 
the depletion of metastasis suppression, therefore, it is 
crucial to re-express the missing gene/protein in order to 
inhibit metastasis. Several drugs have been reported to 
elevate NME1 expression, such as, for example, all-trans 
retinoic acid in hepatocellular carcinoma cell line (47). 
The injection of thujone, a natural product, into nude 
mice bearing B16F-10 melanoma cells, upregulated 
NME1 and increased overall survival (48). Several other 
compounds have been reported to have a similar effect on 
NME1 in vitro: anti-inflammatory compounds such as 
indomethacin and acetylsalicylic acid, antioxidant L-
carnosine, gamma linoleic acid and several others (49). 
The treatment with medroxyprogesterone acetate (MPA) 
induced re-expression of NME1 in triple negative breast 
cancer cells (50) and soft agar colonization was reduced 
by 50% in vitro. Xenograft experiments introducing 
MDA-MB231 cells in vivo revealed 43% less pulmonary 
metastases in MPA treated, versus untreated mice (51). 
Based on these data, a phase II clinical trial with MPA 
treatment was conducted (29), however, unfortunately, 
the patients failed to achieve the necessary plasma levels 
of MPA (52). Another approach that included a cell per-
meable NME1 construct, suppressed pulmonary metas-
tases development in mice while increasing overall sur-
vival (53).
A number of other approaches have been introduced 
over the years of investigation. It has been suggested that 
the NME1/h-Prune protein complex regulates cancer 
progression and that its specific impairment could be a 
new therapeutic strategy. A peptide that disrupts the in-
teraction of NME1 and h-Prune was identified. Preclini-
cal studies on breast and prostate cancer and neuroblas-
toma have proven effectiveness and safety of this procedure 
in a mouse prostate cancer model system (54, 55). An-
other approach is based on the identification of different 
gene targets whose expression is inversely correlated to 
NME1. Lysophosphatidic acid receptor 1 (LPA1) was 
identified as such a target in multiple cancer cell lines and 
breast carcinoma. The use of LPA1 antagonists was veri-
fied in preclinical studies (56).
Although it has been proven that NME1 is downregu-
lated in many aggressive tumor types, until this date it 
hasn’t been established as an independent diagnostic or 
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prognostic marker. Due to its interaction with a number 
of binding proteins, NME1, although expressed, might 
be unavailable, which provides an explanation of why 
NME1 expression is not of independent prognostic im-
portance and, therefore, its expression level, at least for 
now, does not have any clinical value (57). However, since 
the number of interactions involving NME proteins in 
processes contributing to carcinogenesis is considerable it 
is possible that interactions themselves represent a poten-
tial pool of biomarkers or therapeutic targets for disease 
monitoring and treatment. 
Concluding remarks
In the last decades, extensive research has been done 
in order to elucidate the structure, biochemical and bio-
logical functions, evolution and translational research of 
NME/NDPK. Although the knowledge about this gene/
protein family is extensive we are still facing many ques-
tions to be answered in order to fully understand its mul-
tifunctional nature. Besides NME1, NME2 and NME4, 
the knowledge about other family members, including 
the Group I protein NME3, is rather limited. Therefore, 
to get insights on the physiology of others, especially the 
Group II family members, more basic research should be 
supported.
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